A neutral slot exchange so unused CAR-T manufacturing slots go to the next patient
Patients wait weeks for a manufacturing slot while other slots go unused when a patient drops out. A shared booking system would match spare slots to waiting patients.
CAR-T manufacturing slots are allocated per product and per treatment centre, and cancellations (patient deterioration, failed apheresis) leave slots empty while patients at other centres wait. The proposal is a neutral, regulator-sanctioned exchange, run by a registry organisation, where manufacturers post real-time slot availability and treatment centres release and claim slots across products and sites, with priority rules agreed by clinicians. It resembles organ allocation and airline seat inventory systems.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
- Fragmented care and guideline gaps · Patients fall between specialists, wait for referrals and often do not get the treatment guidelines say they should.
Pages like this
not linked directly; found by shared links- IdeaPublic reference standards and potency assays for CAR-T so every lab measures alike
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaTwo-day CAR-T manufacture paired with rapid release tests that regulators accept
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaAn open interoperability standard for closed automated cell-processing machines
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaCollect and freeze T cells at diagnosis for high-risk patients, before chemotherapy
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaMutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaComparability by design: a digital twin and sentinel panel for cell process changes
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaDigital batch records and AI process control to halve cell therapy batch failures
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaHarmonise Europe's hospital exemption for academic cell therapies, with one registry
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.